---
layout: post
title: "Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:58:50 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-08116
original_published: 2022-04-15 00:00:00 +0000
significance: 8.00
---

# Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** April 15, 2022 00:00 UTC
**Document Number:** 2022-08116

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet." This draft guidance addresses FDA's recommendations regarding clinical trials for drugs being developed for the treatment of celiac disease as an adjunct to a gluten-free diet in adults.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/04/15/2022-08116/celiac-disease-developing-drugs-for-adjunctive-treatment-to-a-gluten-free-diet-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-08116

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
